176 related articles for article (PubMed ID: 25963424)
21. Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen.
Chen IC; Hsiao LP; Huang IW; Yu HC; Yeh LC; Lin CH; Wei-Wu Chen T; Cheng AL; Lu YS
Sci Rep; 2017 Aug; 7(1):9842. PubMed ID: 28852212
[TBL] [Abstract][Full Text] [Related]
22. Buparlisib modulates PD-L1 expression in head and neck squamous cell carcinoma cell lines.
Fiedler M; Schulz D; Piendl G; Brockhoff G; Eichberger J; Menevse AN; Beckhove P; Hautmann M; Reichert TE; Ettl T; Bauer RJ
Exp Cell Res; 2020 Nov; 396(1):112259. PubMed ID: 32898555
[TBL] [Abstract][Full Text] [Related]
23. A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer.
McRee AJ; Marcom PK; Moore DT; Zamboni WC; Kornblum ZA; Hu Z; Phipps R; Anders CK; Reeder-Hayes K; Carey LA; Weck KE; Perou CM; Dees EC
Clin Breast Cancer; 2018 Aug; 18(4):289-297. PubMed ID: 29153866
[TBL] [Abstract][Full Text] [Related]
24. Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway.
Maira SM; Furet P; Stauffer F
Future Med Chem; 2009 Apr; 1(1):137-55. PubMed ID: 21426073
[TBL] [Abstract][Full Text] [Related]
25. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?
Zardavas D; Fumagalli D; Loi S
Curr Opin Oncol; 2012 Nov; 24(6):623-34. PubMed ID: 22960556
[TBL] [Abstract][Full Text] [Related]
26. A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.
Ma CX; Luo J; Naughton M; Ademuyiwa F; Suresh R; Griffith M; Griffith OL; Skidmore ZL; Spies NC; Ramu A; Trani L; Pluard T; Nagaraj G; Thomas S; Guo Z; Hoog J; Han J; Mardis E; Lockhart C; Ellis MJ
Clin Cancer Res; 2016 Apr; 22(7):1583-91. PubMed ID: 26563128
[TBL] [Abstract][Full Text] [Related]
27. New strategies in endometrial cancer: targeting the PI3K/mTOR pathway--the devil is in the details.
Myers AP
Clin Cancer Res; 2013 Oct; 19(19):5264-74. PubMed ID: 24089439
[TBL] [Abstract][Full Text] [Related]
28. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.
Slomovitz BM; Coleman RL
Clin Cancer Res; 2012 Nov; 18(21):5856-64. PubMed ID: 23082003
[TBL] [Abstract][Full Text] [Related]
29. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.
Mallon R; Feldberg LR; Lucas J; Chaudhary I; Dehnhardt C; Santos ED; Chen Z; dos Santos O; Ayral-Kaloustian S; Venkatesan A; Hollander I
Clin Cancer Res; 2011 May; 17(10):3193-203. PubMed ID: 21325073
[TBL] [Abstract][Full Text] [Related]
30. The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells.
Brünner-Kubath C; Shabbir W; Saferding V; Wagner R; Singer CF; Valent P; Berger W; Marian B; Zielinski CC; Grusch M; Grunt TW
Breast Cancer Res Treat; 2011 Sep; 129(2):387-400. PubMed ID: 21046231
[TBL] [Abstract][Full Text] [Related]
31. PI3K: A master regulator of brain metastasis-promoting macrophages/microglia.
Blazquez R; Wlochowitz D; Wolff A; Seitz S; Wachter A; Perera-Bel J; Bleckmann A; Beißbarth T; Salinas G; Riemenschneider MJ; Proescholdt M; Evert M; Utpatel K; Siam L; Schatlo B; Balkenhol M; Stadelmann C; Schildhaus HU; Korf U; Reinz E; Wiemann S; Vollmer E; Schulz M; Ritter U; Hanisch UK; Pukrop T
Glia; 2018 Nov; 66(11):2438-2455. PubMed ID: 30357946
[TBL] [Abstract][Full Text] [Related]
32. The PI3K inhibitor buparlisib suppresses osteoclast formation and tumour cell growth in bone metastasis of lung cancer, as evidenced by multimodality molecular imaging.
Wang S; Niu X; Bao X; Wang Q; Zhang J; Lu S; Wang Y; Xu L; Wang M; Zhang J
Oncol Rep; 2019 May; 41(5):2636-2646. PubMed ID: 30896825
[TBL] [Abstract][Full Text] [Related]
33. Effect of Buparlisib, a Pan-Class I PI3K Inhibitor, in Refractory Follicular and Poorly Differentiated Thyroid Cancer.
Borson-Chazot F; Dantony E; Illouz F; Lopez J; Niccoli P; Wassermann J; Do Cao C; Leboulleux S; Klein M; Tabarin A; Eberle MC; Benisvy D; de la Fouchardière C; Bournaud C; Lasolle H; Delahaye A; Rabilloud M; Lapras V; Decaussin-Petrucci M; Schlumberger M
Thyroid; 2018 Sep; 28(9):1174-1179. PubMed ID: 30105951
[TBL] [Abstract][Full Text] [Related]
34. mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy.
O'Regan R; Hawk NN
Expert Opin Ther Targets; 2011 Jul; 15(7):859-72. PubMed ID: 21476875
[TBL] [Abstract][Full Text] [Related]
35. BKM-120 (Buparlisib): A Phosphatidyl-Inositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma.
Speranza MC; Nowicki MO; Behera P; Cho CF; Chiocca EA; Lawler SE
Sci Rep; 2016 Feb; 6():20189. PubMed ID: 26846842
[TBL] [Abstract][Full Text] [Related]
36. [Antihormonal therapy in breast cancer and mTOR inhibitors].
Heudel PÉ; Tredan O; Ray-Coquard I; Treilleux I; Guastalla JP; Bachelot T
Bull Cancer; 2011 Dec; 98(12):1431-7. PubMed ID: 22133994
[TBL] [Abstract][Full Text] [Related]
37. Everolimus and its role in hormone-resistant and trastuzumab-resistant metastatic breast cancer.
Keck S; Glencer AC; Rugo HS
Future Oncol; 2012 Nov; 8(11):1383-96. PubMed ID: 23148612
[TBL] [Abstract][Full Text] [Related]
38. Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study.
Vansteenkiste JF; Canon JL; De Braud F; Grossi F; De Pas T; Gray JE; Su WC; Felip E; Yoshioka H; Gridelli C; Dy GK; Thongprasert S; Reck M; Aimone P; Vidam GA; Roussou P; Wang YA; Di Tomaso E; Soria JC
J Thorac Oncol; 2015 Sep; 10(9):1319-1327. PubMed ID: 26098748
[TBL] [Abstract][Full Text] [Related]
39. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
[TBL] [Abstract][Full Text] [Related]
40. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
